Novartis emerged as an attractive investment choice with considerable edge over its biotech competitors. Deutsche Bank raised its price target due to optimism surrounding
Pluvicto. Several institutions identified Novartis as an appealing
value and
momentum stock, and Barclays increased their earnings projections given strong prescription rates in the US. The Sandoz family foundation offered $3 billion worth of the company's shares as
Novartis consistently secures FDA approvals, especially in their kidney disease portfolio. Some setbacks were faced as Novartis's key drug faced upcoming competition and Q4 witnessed lagging sales. However, the delegation inked a significant licensing agreement with PTC Therapeutics and secured a historic
FDA approval for the treatment of a rare kidney disease. Despite the volatility in the market, Novartis delivered an impressive Q4 with an EPS beat and subsequently increased its dividend. Although there was a brief dip in stock prices, overall confidence in the stock remains due to potential
long-term growth.
Novartis Stocks News Analytics from Mon, 08 Jul 2024 07:00:00 GMT to Thu, 03 Apr 2025 20:25:00 GMT -
Rating 8
- Innovation 5
- Information 9
- Rumor 3
